March 15, 2021
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Brickell Biotech, Inc.
Registration Statement on Form S-3
File Number 333-254037
Ladies and Gentlemen:
Brickell Biotech, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-3 be accelerated so that it will become effective at 4:00 p.m. Eastern time on March 17, 2021, or as soon thereafter as practicable.
Please telephone the undersigned (305-582-4657) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
| | | | | | | | | | | |
|
| | | |
| | Very truly yours, | |
| | | |
| | BRICKELL BIOTECH, INC.
| |
| | By: | /s/ Andrew Sklawer | |
| | | Name: Andrew Sklawer | |
| | | Title: Chief Operating Officer | |
